Targeting MERTK on tumour cells and macrophages: a potential intervention for sporadic and NF2-related meningioma and schwannoma tumours-Reference-Cited by-同舟云学术

Targeting MERTK on tumour cells and macrophages: a potential intervention for sporadic and NF2-related meningioma and schwannoma tumours

Published:2024-08-23 Issue: Volume: Page:
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Dave Foram,Herrera Kevin,Lockley Alex,van de Weijer Laurien L.,Henderson Summer,Sofela Agbolahan A.,Hook Laura,Adams Claire L.,Ercolano Emanuela,Hilton David A.,Maze Emmanuel A.,Kurian Kathreena M.,Ammoun Sylwia^ORCID,Hanemann C. Oliver^ORCID

Funder

Animal Free Research UK

Brain Tumour Research https://braintumourresearch.org/

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41388-024-03131-z.pdf

Reference70 articles.

1. Plotkin SR, Messiaen L, Legius E, Pancza P, Avery RA, Blakeley JO, et al. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation. Genet Med. 2022;24:1967–77.

2. Blakeley JO, Evans DG, Adler J, Brackmann D, Chen R, Ferner RE, et al. Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A. 2012;158A:24–41.

3. Agnihotri S, Jalali S, Wilson MR, Danesh A, Li M, Klironomos G, et al. The genomic landscape of schwannoma. Nat Genet. 2016;48:1339–48.

4. Wang JZ, Nassiri F, Mawrin C, Zadeh G. Genomic Landscape of Meningiomas. Adv Exp Med Biol. 2023;1416:137–58.

5. Champeaux-Depond C, Weller J, Resche-Rigon M. Neurofibromatosis type 2: a nationwide population-based study focused on survival after meningioma surgery. Clin Neurol Neurosurg. 2020;198:106236.